B. Kim

发表

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis

B. Han, J. H. Kim, H. Kim, 2018, Journal of Cancer.

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis

J. H. Kim, H. Kim, B. Kim, 2018, Journal of Cancer.

The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis

H. Jang, J. H. Kim, H. Kim, 2017, Oncotarget.

Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review

H. Jang, J. H. Kim, H. Kim, 2017, Oncotarget.

KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review

H. Jang, J. H. Kim, H. Kim, 2016, Oncotarget.

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers

H. Jang, J. H. Kim, H. Kim, 2017, Journal of Cancer.

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

J. H. Kim, J. H. Kim, H. Kim, 2016, Journal of Cancer.

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

PWWP2B promotes DNA end resection and homologous recombination

Semin Lee, K. Myung, Hongtae Kim, 2022, EMBO reports.

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44

S. Sohn, B. Kim, D. Zang, 2022, Cancers.

Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels

Bohyun Kim, S. Sohn, H. Kim, 2020, International journal of molecular sciences.

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis.

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis

Bum Jun Kim, H. Jang, Jung Han Kim, 2017, Oncotarget.

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients

H. Chang, Myung-Hwan Kim, D. Park, 2017, Cancer Chemotherapy and Pharmacology.

Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience

J. H. Kim, H. Kim, B. Kim, 2017, Indian Journal of Hematology and Blood Transfusion.

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2021, Therapeutic advances in medical oncology.

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis

J. H. Kim, H. Kim, B. Kim, 2018, The Korean journal of internal medicine.

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

Jung Woo Lee, J. W. Kim, Jong Hyeok Kim, 2021, Journal of Cancer.

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer

I. Hwang, B. Han, J. H. Kim, 2022, Journal of Cancer.

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen

Tae Won Kim, H. Chang, Jae-Lyun Lee, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials

H. Jang, J. H. Kim, H. Kim, 2017, Oncotarget.

Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts.

H. Chang, Myung-Hwan Kim, D. Park, 2017 .

Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials

H. Jang, J. H. Kim, H. Kim, 2018, Gastroenterology research and practice.

An integrated mRNA–microRNA regulatory network identified INHBA and has-miR-135a-5p as predictors of gastric cancer recurrence

Semin Lee, S. Sohn, H. Kim, 2021 .

An integrated mRNA–microRNA regulatory network identified INHBA and has-miR-135a-5p as predictors of gastric cancer recurrence

S. Sohn, H. Kim, B. Kim, 2021, Molecular & Cellular Toxicology.

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

H. Chang, B. Ryoo, B. Kim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis

H. Jang, J. H. Kim, H. Kim, 2017, Oncotarget.

Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients

H. Chang, B. Ryoo, S. Park, 2017, British Journal of Cancer.

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

Dong Sook Kim, S. Park, Keun-Wook Lee, 2022, Gastric Cancer.

Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis

H. Jang, S. Park, J. H. Kim, 2018, Journal of Cancer.

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression

S. Sohn, H. Kim, B. Kim, 2021, International journal of molecular sciences.

Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review

H. Jang, J. H. Kim, H. Kim, 2017, Cancer Chemotherapy and Pharmacology.

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer

Bohyun Kim, S. Sohn, H. Kim, 2021, Journal of Cancer.

The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review

H. Jang, J. H. Kim, H. Kim, 2017, Oncotarget.

Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group

Min Hwan Kim, Dong Sook Kim, Yeon-Hee Park, 2022, Therapeutic advances in medical oncology.

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

H. Jang, J. H. Kim, B. Kim, 2017, Oncotarget.

Erratum: Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

C. Shin, W. Koom, B. Eom, 2019, Journal of gastric cancer.

Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification

Yoo-Jin Kim, Bohyun Kim, S. Sohn, 2020, Investigational New Drugs.

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine

J. W. Kim, Keun-Wook Lee, Sook Ryun Park, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Erratum: Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

C. Shin, W. Koom, B. Eom, 2023, Journal of Gastric Cancer.

Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer

C. Nam, S. Rha, H. Jeung, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.

Yoon-Koo Kang, J. W. Kim, Keun-Wook Lee, 2023, Journal of Clinical Oncology.

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis

J. H. Kim, H. Kim, B. Kim, 2017, Oncotarget.